DermDocs

This is the first episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma and hosted by prurigo nodularis (PN) expert Dr. Shawn Kwatra, MD. This episode, "Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis", featuring expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, discusses the following topics:

• The lack of awareness and timely, correct diagnosis of PN patients

• Strategies for assessing patients with PN and alleviating disease symptoms and burden

• Examining the current expert guidance and available therapies for treating PN

• Looking to the future of PN diagnosis and targeted treatment

This is the second episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "New Therapies and Expert Strategies for Long-term Control", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics:

1. The pros and cons of steroid use in treating AD

2. Targeted non-steroidal topical therapies approved by the FDA

3. Relevant clinical efficacy and safety data for new and emerging non-steroidal topicals

4. Recommendations for long-term symptom control in AD patients

This is the fifth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?", featuring expert dermatologist Dr. Naiem Issa, MD, PhD, discusses the following topics:

1. Mechanistic differences between JAKi and biologics for treatment of AD

2. Clinical data supporting the safety of JAKi in head-to-head trials compared to biologics

3. Pearls for prescribing JAKi to AD patients

4. Strategies for choosing JAKi vs biologics based on safety and patient factors

This is the first episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Dangers and Side Effects of Steroid Exposure in Treatment of AD", featuring expert dermatologist Dr. Peter Lio, MD, discusses the following topics:

• Side effects of topical and oral corticosteroid exposure

• Pearls and gaps in current guidelines for treatment of AD

• Identifying topical steroid withdrawal symptoms

• Safety and stewardship strategies for topical steroids

• Future of non-steroidal advanced topical therapies for AD

Record Date: 8/6/2024

This is the fourth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy", featuring expert dermatologist Dr. Ruth Ann Vleugels, MD, MPH discusses the following topics:

• Identifying ideal candidates for oral JAK inhibitor therapy

• Steps to initiate therapy and onboard new patients

• How to manage side effects and maintain adherence to treatment

• Case examples and real-world data

This is the third episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics:

1. Overall impact of atopic dermatitis on patients' quality of life

2. Overview of the role of various existing treatments for AD and expert guidelines

3. Discussion of LEVEL UP clinical trial data comparing upadacitinib and dupilumab

4. Defining treatment success and best practices for treatment selection

www.livderm.org

This special podcast episode, developed in collaboration with UCB, features LiVDerm faculty and esteemed dermatologists Dr. Jennifer Hsiao, MD, and Dr. Hadar Lev-Tov, MD. As experts in all things hidradenitis suppurativa (HS), our faculty discuss the need for early and accurate diagnosis and assessment of patients with HS in order to prescribe treatment at the best time to achieve disease control, including the following topics:

1. Key challenges in treating patients with moderate-to-severe HS

2. The role of targeted, systemic therapies in HS management

3. Defining "moderate" disease and strategies for severity assessment

4. Defining window of opportunity and strategies for advanced treatment of HS

5. Defining and assessing treatment response and success with targeted therapies

This is the second episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis", featuring expert dermatologist Dr. James Song, MD, discusses the following topics:

1. Short- and long-term efficacy and safety data for JAK inhibitor therapies 

2. New topline data from the LEVEL UP trial studying upadacitinib in comparison to dupilumab for the treatment of patients aged 12 years and older with moderate-to-severe AD 

3. Head-to-head studies and real-world evidence evaluating JAK inhibitor therapies 

4. Emerging clinical developments and what's coming next in JAK inhibitor research 

This is the fourth and final episode of the, "Psoriasis in Skin of Color Unplugged" series, hosted by expert dermatologist Dr. Mona Shahriari who will be discussing the gaps in care for psoriasis patients with skin of color. This episode, “Patient and Disease Advocacy”, featuring Jason Harris, the VP of Government Relations and Advocacy at the National Psoriasis Foundation (NPF), discusses the following topics:

1. Patient perspective on challenges to receiving treatment for their psoriasis 

2. NPF efforts to address patient challenges and access to care issues 

3. Relevant survey and research data on disparities specific to SoC and socioeconomic status 

4. Consideration of impact on quality of life in determining access to systemic treatments 

If you have any questions about NPF efforts to advocate for patients with psoriasis, please reach out to Jason Harris via email at [email protected] or visit the NPF website. 

This is the third episode of the, "Psoriasis in Skin of Color Unplugged" series, hosted by expert dermatologist Dr. Mona Shahriari who will be discussing the gaps in care for psoriasis patients with skin of color. This episode, “Advancing Diversity and Inclusion in Clinical Trials”, featuring expert dermatologists Dr. Andrew Alexis and Dr. Jennifer Soung, discusses the following topics:

1. Underrepresentation of diverse patients, investigators, and trial sites in clinical studies

2. FDA efforts to improve clinical trial diversity and education

3. The impact that current clinical trials focusing on SOC are having on patient care

4. High-level findings from the VISIBLE trial studying psoriasis patients of color

www.LiVDerm.org